BrightGene Bio-Medical Technology Co Ltd
SSE:688166
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
20.3
39.25
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one BrightGene Bio-Medical Technology Co Ltd stock under the Base Case scenario is 22.57 CNY. Compared to the current market price of 31.54 CNY, BrightGene Bio-Medical Technology Co Ltd is Overvalued by 28%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
BrightGene Bio-Medical Technology Co Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for BrightGene Bio-Medical Technology Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
BrightGene Bio-Medical Technology Co Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
BrightGene Bio-Medical Technology Co Ltd
Balance Sheet Decomposition
BrightGene Bio-Medical Technology Co Ltd
Current Assets | 1.4B |
Cash & Short-Term Investments | 505.4m |
Receivables | 374.8m |
Other Current Assets | 502.3m |
Non-Current Assets | 3.5B |
Long-Term Investments | 244m |
PP&E | 2.7B |
Intangibles | 107.6m |
Other Non-Current Assets | 423.8m |
Current Liabilities | 885.5m |
Accounts Payable | 174.1m |
Accrued Liabilities | 14.6m |
Short-Term Debt | 161.9m |
Other Current Liabilities | 534.9m |
Non-Current Liabilities | 1.6B |
Long-Term Debt | 1.6B |
Other Non-Current Liabilities | 68m |
Earnings Waterfall
BrightGene Bio-Medical Technology Co Ltd
Revenue
|
1.2B
CNY
|
Cost of Revenue
|
-559.1m
CNY
|
Gross Profit
|
682.4m
CNY
|
Operating Expenses
|
-476.2m
CNY
|
Operating Income
|
206.2m
CNY
|
Other Expenses
|
-18.1m
CNY
|
Net Income
|
188.1m
CNY
|
Free Cash Flow Analysis
BrightGene Bio-Medical Technology Co Ltd
CNY | |
Free Cash Flow | CNY |
Profitability Score
Profitability Due Diligence
BrightGene Bio-Medical Technology Co Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
BrightGene Bio-Medical Technology Co Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
BrightGene Bio-Medical Technology Co Ltd's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
BrightGene Bio-Medical Technology Co Ltd's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
BrightGene Bio-Medical Technology Co Ltd
According to Wall Street analysts, the average 1-year price target for BrightGene Bio-Medical Technology Co Ltd is 45.09 CNY with a low forecast of 44.65 CNY and a high forecast of 46.42 CNY.
Dividends
Current shareholder yield for BrightGene Bio-Medical Technology Co Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
BrightGene Bio-Medical Technology Co., Ltd. engages in the research, development, and manufacturing of biopharmaceuticals, medicines as well as special generic active pharmaceutical ingredients and finished dosage forms. The company is headquartered in Suzhou, Jiangsu and currently employs 910 full-time employees. The company went IPO on 2019-11-08. The firm's main products include antifungal active pharmaceutical ingredients (APIs), antiviral APIs, immunosuppressive APIs, and other APIs and preparations. The firm's generic drugs mainly include entecavir, caspofungin, micafungin, posaconazole, everolimus and fondaparinux sodium. The firm mainly conducts its businesses in domestic and overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one BrightGene Bio-Medical Technology Co Ltd stock under the Base Case scenario is 22.57 CNY.
Compared to the current market price of 31.54 CNY, BrightGene Bio-Medical Technology Co Ltd is Overvalued by 28%.